Founder sentenced 2022 · $9bn peak valuation
Theranos
A blood-testing company valued in the billions on technology that did not work, whose founder was convicted of defrauding investors of hundreds of millions of dollars.
What happened
Theranos promised to run a wide range of diagnostic tests from a few drops of blood, on proprietary devices, at a fraction of conventional cost. It raised very large sums at a valuation reported at around $9bn, and assembled a board of exceptional public standing that contained almost nobody with expertise in laboratory diagnostics.
The technology did not do what was claimed. Reporting, regulatory findings and eventually the courts established that tests were being run on modified conventional analysers rather than on the company's own devices, and that investors had been given a materially false account of the company's capabilities and commercial position.
In November 2022 the founder, Elizabeth Holmes, was sentenced to 135 months — eleven years and three months — for defrauding Theranos investors of hundreds of millions of dollars, according to the US Department of Justice. Her sentence has since been reduced.
The part that matters for an angel is not the drama. It is that the deception was in a domain where independent verification was available and unusually cheap: the company's claims were about laboratory science, and laboratory scientists were reachable.
Visible at the time
What an investor could have seen
These are things that were observable before the collapse, not hindsight dressed as foresight. Some failures genuinely could not be seen coming; where that is the case, this section says so rather than inventing a warning.
- A board of eminent people with no expertise in the company's actual technical domain.
- Refusal to permit independent validation of the core technology, on trade-secret grounds.
- No peer-reviewed publication of results in a field where publication is the norm.
- Extreme secrecy about the product presented as competitive necessity.
- Commercial partnerships described in terms that partners themselves did not use.
For your own diligence
What to do differently
- In any technical or regulated domain, an hour with an independent practitioner is the highest-value diligence available. Diagnostics has thousands of them, and the claims here were of a kind they could have assessed immediately.
- Treat a refusal to permit technical validation as a finding, not as an inconvenience. Trade-secret concerns are real and are routinely handled with confidentiality agreements and limited-scope review; a blanket refusal is different in kind.
- A prestigious board is not diligence. It is a signal about the founder's ability to attract prestigious people, which is a different and much less useful fact.
- Where regulation exists, check the regulator's own record rather than the company's description of its regulatory position.
Checked, not remembered
Sources
Legal outcomes on these pages move — convictions are appealed, sentences reduced, pardons and commutations granted. Every status here is stated with the date it was accurate to, and every figure is traceable to the reporting linked below.
The mechanics
Terms this turns on
Theranos: common questions
Could an ordinary angel have avoided Theranos?
What was actually proven in court?
Keep reading